Zeng Xianmin, Rao Mahendra S
Buck Institute for Age Research, 8001 Redwood Boulevard, Novato, CA 94945, USA.
Curr Opin Mol Ther. 2006 Aug;8(4):338-44.
Most therapeutic uses of stem cells demand that large numbers of cells are maintained in a Good Manufacturing Practice (GMP) facility, and envisage the development of a master depository from which a working bank of cells can be retrieved and differentiated into an appropriate phenotype for use. Likewise for gene- and drug-discovery processes, it is assumed that stable and genetically identical cells will eventually become available in large numbers. Critical for both of these assumptions is that the stem cells are stable during periods of amplification and differentiation. This review discusses the physiological features that must be assessed to measure stem cell stability, and proposes that genomic, epigenomic and mitochondrial markers, as well as functional measures of utility, should be considered. Recent findings suggesting that the level of cell stability is not homogeneous throughout all stem cells are also discussed.
干细胞的大多数治疗用途都要求在良好生产规范（GMP）设施中维持大量细胞，并设想建立一个主储存库，从中可以提取细胞工作库并将其分化为合适的表型以供使用。同样，对于基因和药物发现过程，假定最终将能够大量获得稳定且基因相同的细胞。这两个假设的关键在于干细胞在扩增和分化期间是稳定的。本综述讨论了为测量干细胞稳定性而必须评估的生理特征，并提出应考虑基因组、表观基因组和线粒体标记以及功能效用指标。还讨论了最近的研究结果，这些结果表明并非所有干细胞的细胞稳定性水平都是均匀的。
